Exagen's better-than-expected Q1 2024 earnings and sales figures suggest operational efficiency and growth, likely leading to increased investor confidence and a positive short-term impact on the stock price. The significant beat on both EPS and sales estimates, along with year-over-year growth, highlights the company's strong performance and potential for future gains.